CIK 0001439222
- Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-04-02 | Schenkein David P Chief Executive Officer | Option exercise | +13,000 | $0.30 | $4K | 13,000 |
| 2018-04-02 | Schenkein David P Chief Executive Officer | Sale | −1,557 | $75.54 | $118K | 11,443 |
| 2018-04-02 | Schenkein David P Chief Executive Officer | Sale | −2,600 | $76.40 | $199K | 8,843 |
| 2018-04-02 | Schenkein David P Chief Executive Officer | Sale | −3,340 | $77.76 | $260K | 5,503 |
| 2018-04-02 | Schenkein David P Chief Executive Officer | Sale | −3,390 | $78.59 | $266K | 2,113 |
| 2018-04-02 | Schenkein David P Chief Executive Officer | Sale | −2,113 | $79.49 | $168K | 0 |
| 2018-04-02 | Schenkein David P Chief Executive Officer | Option exercise · Stock option (right to buy) | −13,000 | 78,567 | ||
| 2018-03-28 | Biller Scott Chief Scientific Officer | Option exercise · Stock option (right to buy) | −37 | 1,766 | ||
| 2018-03-28 | Biller Scott Chief Scientific Officer | Option exercise · Stock option (right to buy) | −4,100 | 27,718 | ||
| 2018-03-28 | Biller Scott Chief Scientific Officer | Option exercise | +37 | $0.47 | $17 | 53,096 |
| 2018-03-28 | Biller Scott Chief Scientific Officer | Option exercise | +4,100 | $2.34 | $10K | 57,196 |
| 2018-03-28 | Biller Scott Chief Scientific Officer | Option exercise · Stock options (right to buy) | +37 | 1,766 | ||
| 2018-03-28 | Biller Scott Chief Scientific Officer | Option exercise · Stock options (right to buy) | +4,100 | 27,718 | ||
| 2018-03-22 | Hoerter Steven L. Chief Commercial Officer | Option exercise | +2,050 | $39.76 | $82K | 2,050 |
| 2018-03-22 | Hoerter Steven L. Chief Commercial Officer | Sale | −2,050 | $84.65 | $174K | 0 |
| 2018-03-22 | Hoerter Steven L. Chief Commercial Officer | Option exercise · Stock option (right to buy) | −2,050 | 70,900 | ||
| 2018-03-19 | Foster-Cheek Kaye I Director | Option exercise | +6,800 | $47.33 | $322K | 9,000 |
| 2018-03-19 | Foster-Cheek Kaye I Director | Sale | −6,800 | $81.97 | $557K | 2,200 |
| 2018-03-19 | Foster-Cheek Kaye I Director | Option exercise · Stock option (right to buy) | −6,800 | 0 | ||
| 2018-03-16 | Scadden David Director | Purchase | +200 | $83.44 | $17K | 571 |
Page 64 of 80 · 1,590 trades